Affimed NV (Affimed NV) EV-to-Revenue : 2.82 (As of May. 05, 2024)

View and export this data going back to 2014. Start your Free Trial

What is Affimed NV EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Affimed NV's enterprise value is $25.08 Mil. Affimed NV's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $8.88 Mil. Therefore, Affimed NV's EV-to-Revenue for today is 2.82.

The historical rank and industry rank for Affimed NV's EV-to-Revenue or its related term are showing as below:

AFMD' s EV-to-Revenue Range Over the Past 10 Years
Min: -1.94 Med: 6.68 Max: 136.19
Current: 2.82

During the past 12 years, the highest EV-to-Revenue of Affimed NV was 136.19. The lowest was -1.94. And the median was 6.68.

AFMD's EV-to-Revenue is ranked better than
74.81% of 1036 companies
in the Biotechnology industry
Industry Median: 7.98 vs AFMD: 2.82

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-05-05), Affimed NV's stock price is $5.42. Affimed NV's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.59. Therefore, Affimed NV's PS Ratio for today is 9.12.

Affimed NV EV-to-Revenue Historical Data

The historical data trend for Affimed NV's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Affimed NV EV-to-Revenue Chart

Affimed NV Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EV-to-Revenue

Get a 7-Day Free Trial

4.07

11.45

10.50

0.07

3.92

Affimed NV Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EV-to-Revenue	Get a 7-Day Free Trial															0.07	-0.96	-0.74	-0.50	3.92

Competitive Comparison of Affimed NV's EV-to-Revenue

For the Biotechnology subindustry, Affimed NV's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Affimed NV's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Affimed NV's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Affimed NV's EV-to-Revenue falls into.

Affimed NV EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Affimed NV's EV-to-Revenue for today is calculated as:

EV-to-Revenue	=	Enterprise Value (Today)	/	Revenue (TTM)
	=	25.079	/	8.879
	=	2.82

Affimed NV's current Enterprise Value is $25.08 Mil.
Affimed NV's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $8.88 Mil.

Affimed NV (NAS:AFMD) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Affimed NV's PS Ratiofor today is calculated as:

PS Ratio	=	Share Price (Today)	/	Revenue per Share (TTM)
	=	5.42	/	0.594
	=	9.12

Affimed NV's share price for today is $5.42.
Affimed NV's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.59.

Affimed NV EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Affimed NV's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Affimed NV (Affimed NV) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Affimed NV (NAS:AFMD) » Definitions » EV-to-Revenue

Comparable Companies

Traded in Other Exchanges

A28:Germany

Address

Im Neuenheimer Feld 582, Technologiepark, Heidelberg, BW, DEU, 69120

Website

https://www.affimed.com

Affimed NV is a clinical-stage biopharmaceutical company. The company is engaged in discovering and developing targeted cancer immunotherapies. Its product candidates are being developed in the field of immuno-oncology, which represents an approach to cancer treatment that seeks to harness the body's immune defenses to fight tumor cells. The company is also developing single and combination therapies to treat cancers and other life-threatening diseases. Geographically, it derives a majority of revenue from the United States and also has a presence in Europe and Germany.